• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

    26.23 +0.31 (+1.20%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,050,004
    Open 26.24
    Bid (Size) 25.90 (100)
    Ask (Size) 27.00 (500)
    Prev. Close 25.92
    Today's Range 25.82 - 26.82
    52wk Range 14.03 - 31.77
    Shares Outstanding 50,241,789
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup ↗
    Via Chartmill
    News headline image
    Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability ↗
    Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    -9.6%
    -9.6%
    1 Month
    -3.3%
    -3.3%
    3 Month
    +26.8%
    +26.8%
    6 Month
    -2.4%
    -2.4%
    1 Year
    +84.6%
    +84.6%

    More News

    Read More
    News headline image
    Arcutis Biotherapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance ↗
    Via Chartmill
    News headline image
    Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup ↗
    Via Chartmill
    Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
    Via Chartmill
    Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ↗
    Via Chartmill
    News headline image
    Arcutis Expands Board of Directors with Appointment of Chris Peetz
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% ↗
    Via The Motley Fool
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price ↗
    Via Chartmill
    Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗
    Via Chartmill
    News headline image
    Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗
    Via MarketBeat
    News headline image
    Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis (ARQT) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate ↗
    Via Chartmill
    News headline image
    Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
    Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
    What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
    Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
    The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
    What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
    The current price of Arcutis Biotherapeutics, Inc. - Common stock is 26.23
    When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
    The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 08/11/26 04:00 PM ET
    What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
    The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.32B
    How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
    Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.